-transparent.png){kind=logo}
Four isolated vessels that are monoreceptor systems for neurokinins, the dog carotid artery and rabbit jugular vein (NK-1), the rabbit pulmonary artery (NK-2) and the rat portal vein (NK-3), were used to compare the activities of selective neurokinin agonists and evaluate the affinities of new NK-3 antagonists. Chemical modifications in the partial sequences NKA (4-10) and NKB (4-10), particularly the replacement of Val7 with an aromatic residue (Tyr, MePhe or Trp) and the extension of the peptide backbone in position 8, obtained with beta-Ala, led to compounds that maintain weak agonistic activities on the NK-1 and NK-2, and some of them also on NK-3 receptors but exert potent antagonism against NKB on the NK-3 receptor of the rat portal vein. Antagonistic affinity is the highest when Trp is used in position 7 of [beta-Ala8]-NKA (4-10) and MePhe in position 7 of [beta-Ala8]-NKB (4-10). Antagonism is selective for NKB or [MePhe7]-NKB, and appears to be specific, since the most active compound [Trp7, beta-Ala8]-NKA (4-10) is inactive against bradykinin on the rabbit jugular vein (B2 receptor), against SP on the rabbit jugular vein (NK-1 receptor), against desArg9-bradykinin on the rabbit aorta (B1 receptor), and against angiotensin II and histamine (AT and H receptors, respectively) in the rabbit aorta. The new NK-3 receptor antagonists described in the present study provide useful tools for neurokinin receptor characterization and for determining the roles of neurokinins in physiopathology.
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
July 1992,
Journal of medicinal chemistry,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
January 2005,
Progress in medicinal chemistry,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
June 1998,
Bioorganic & medicinal chemistry letters,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
February 2021,
Climacteric : the journal of the International Menopause Society,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
April 2023,
Lancet (London, England),
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
January 2015,
CNS & neurological disorders drug targets,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
November 1995,
Farmaco (Societa chimica italiana : 1989),
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
June 1991,
Neuropeptides,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
January 1998,
Progress in medicinal chemistry,
G Drapeau, and
N Rouissi, and
F Nantel, and
N E Rhaleb, and
C Tousignant, and
D Regoli
April 2000,
Expert opinion on investigational drugs,
